Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with

GlobeNewswireMay 30 07:30 ET

Press Release: Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Dyne

Dow JonesMay 28 07:30 ET

Jefferies Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $42

Jefferies analyst Andrew Tsai maintains $Dyne Therapeutics(DYN.US)$ with a buy rating, and maintains the target price at $42.According to TipRanks data, the analyst has a success rate of 46.2% and a t

moomoo NewsMay 23 09:33 ET

Dyne Therapeutics: A Strong Buy on Promising Drug Performance and Market Potential

TipRanksMay 23 08:56 ET

J.P. Morgan Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Announces Target Price $39

J.P. Morgan analyst Tessa Romero maintains $Dyne Therapeutics(DYN.US)$ with a buy rating, and sets the target price at $39.According to TipRanks data, the analyst has a success rate of 49.0% and a tot

moomoo NewsMay 23 07:33 ET

Dyne Therapeutics Insider Sold Shares Worth $1,002,751, According to a Recent SEC Filing

Oxana Beskrovnaya, Chief Scientific Officer, on May 20, 2024, sold 30,426 shares in Dyne Therapeutics (DYN) for $1,002,751. Following the Form 4 filing with the SEC, Beskrovnaya has control over a tot

MT NewswiresMay 23 03:25 ET